Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study.
Anticoagulants
Clinical trial, phase IV
Haemorrhage
Off-label use
Stroke
Thromboembolism
Journal
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
ISSN: 1568-5888
Titre abrégé: Neth Heart J
Pays: Netherlands
ID NLM: 101095458
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
accepted:
21
10
2020
pubmed:
8
1
2021
medline:
8
1
2021
entrez:
7
1
2021
Statut:
ppublish
Résumé
Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban. With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15-50 ml/min, weight ≤60 kg, and/or use of strong p‑glycoprotein inhibitors) of patients from Belgium and the Netherlands (BeNe) with those from other European countries (OEC). Of all 13,639 patients in ETNA-AF-Europe, 2579 were from BeNe. BeNe patients were younger than OEC patients (mean age: 72.3 vs 73.9 years), and had lower CHA There were several notable differences between BeNe and OEC regarding clinical characteristics and dosing practices in patients prescribed edoxaban, which are relevant for the local implementation of dose evaluation and optimisation. NCT02944019; Date of registration 24 October 2016.
Sections du résumé
BACKGROUND
BACKGROUND
Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban.
METHODS
METHODS
With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15-50 ml/min, weight ≤60 kg, and/or use of strong p‑glycoprotein inhibitors) of patients from Belgium and the Netherlands (BeNe) with those from other European countries (OEC).
RESULTS
RESULTS
Of all 13,639 patients in ETNA-AF-Europe, 2579 were from BeNe. BeNe patients were younger than OEC patients (mean age: 72.3 vs 73.9 years), and had lower CHA
CONCLUSION
CONCLUSIONS
There were several notable differences between BeNe and OEC regarding clinical characteristics and dosing practices in patients prescribed edoxaban, which are relevant for the local implementation of dose evaluation and optimisation.
TRIAL REGISTRATION
BACKGROUND
NCT02944019; Date of registration 24 October 2016.
Identifiants
pubmed: 33411231
doi: 10.1007/s12471-020-01518-7
pii: 10.1007/s12471-020-01518-7
pmc: PMC7904979
doi:
Banques de données
ClinicalTrials.gov
['NCT02944019']
Types de publication
Journal Article
Langues
eng
Pagination
158-167Références
Lancet. 2015 Jun 6;385(9984):2288-95
pubmed: 25769361
BMJ Open. 2019 Apr 20;9(4):e026645
pubmed: 31005934
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Am Heart J. 2017 Dec;194:132-140
pubmed: 29223431
N Engl J Med. 2011 Sep 15;365(11):981-92
pubmed: 21870978
Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):28-36
pubmed: 27680880
Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):174-181
pubmed: 29141274
Thromb J. 2019 Apr 25;17:7
pubmed: 31169831
Thromb Haemost. 2017 Dec;117(12):2376-2388
pubmed: 29212125
BMJ. 2018 Jul 4;362:k2505
pubmed: 29973392
Thromb Haemost. 2018 Mar;118(3):526-538
pubmed: 29359278
Cardiol Ther. 2016 Jun;5(1):1-18
pubmed: 26935434
BMC Cardiovasc Disord. 2019 Jul 12;19(1):165
pubmed: 31299906
Thromb J. 2018 Apr 18;16:7
pubmed: 29692686
J Am Heart Assoc. 2018 Feb 16;7(4):
pubmed: 29453305
Br J Clin Pharmacol. 2020 Mar;86(3):533-547
pubmed: 31631392
Am J Med. 2019 Jul;132(7):847-855.e3
pubmed: 30776320
N Engl J Med. 2013 Nov 28;369(22):2093-104
pubmed: 24251359
J Am Coll Cardiol. 2017 Jun 13;69(23):2779-2790
pubmed: 28595692
N Engl J Med. 2011 Sep 8;365(10):883-91
pubmed: 21830957
Br J Clin Pharmacol. 2019 Feb;85(2):422-431
pubmed: 30423191
Front Pharmacol. 2018 Oct 30;9:1220
pubmed: 30425641
N Engl J Med. 2009 Sep 17;361(12):1139-51
pubmed: 19717844
Eur Heart J. 2018 Apr 21;39(16):1330-1393
pubmed: 29562325
Egypt Heart J. 2018 Dec;70(4):307-313
pubmed: 30591748
J Cardiovasc Med (Hagerstown). 2019 Feb;20(2):97-104
pubmed: 30540648
Int J Clin Pharm. 2015 Dec;37(6):1128-35
pubmed: 26243531